Stock 455 TIANDA PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tianda Pharmaceuticals Limited

Equities

455

KYG887471038

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 09:48:43 2024-04-28 pm EDT 		5-day change 1st Jan Change
0.265 HKD 0.00% Intraday chart for Tianda Pharmaceuticals Limited +1.92% +21.56%
Mar. 26 Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024 CI
Mar. 26 Tianda Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 645.2 468.7 369.8 296.7 688 870.8
Enterprise Value (EV) 1 245.9 -28.93 -78.38 8.636 595.6 646.6
P/E ratio 51.9 x 46.9 x 139 x 94.5 x -25.4 x -15.9 x
Yield 1.9% 1.61% 0.64% 0.94% 0.81% 0.86%
Capitalization / Revenue 3.3 x 1.3 x 0.7 x 0.6 x 1.45 x 1.59 x
EV / Revenue 1.26 x -0.08 x -0.15 x 0.02 x 1.26 x 1.18 x
EV / EBITDA 6.33 x -0.78 x -3.09 x 0.38 x -28.6 x -23.2 x
EV / FCF 7.82 x -0.5 x 0.67 x -0.07 x -3.23 x 6.34 x
FCF Yield 12.8% -201% 150% -1,430% -31% 15.8%
Price to Book 0.83 x 0.55 x 0.48 x 0.41 x 0.91 x 1.39 x
Nbr of stocks (in thousands) 2,150,636 2,150,042 2,150,042 2,150,042 2,150,042 2,150,042
Reference price 2 0.3000 0.2180 0.1720 0.1380 0.3200 0.4050
Announcement Date 7/27/17 7/26/18 7/25/19 7/28/20 7/23/21 4/28/23
1HKD in Million2HKD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 195.5 361.6 527 491.5 474.3 546.7
EBITDA 1 38.85 37.02 25.4 22.94 -20.84 -27.88
EBIT 1 17.45 14.97 9.232 9.471 -34.36 -70.14
Operating Margin 8.93% 4.14% 1.75% 1.93% -7.24% -12.83%
Earnings before Tax (EBT) 1 32.75 29.94 26.17 15.93 -27.44 -63.85
Net income 1 12.44 10.01 2.657 3.143 -27.14 -54.64
Net margin 6.36% 2.77% 0.5% 0.64% -5.72% -9.99%
EPS 2 0.005785 0.004653 0.001235 0.001461 -0.0126 -0.0254
Free Cash Flow 1 31.44 58.28 -117.6 -123.5 -184.5 101.9
FCF margin 16.08% 16.12% -22.31% -25.12% -38.9% 18.64%
FCF Conversion (EBITDA) 80.94% 157.46% - - - -
FCF Conversion (Net income) 252.71% 582.38% - - - -
Dividend per Share 2 0.005700 0.003500 0.001100 0.001300 0.002600 0.003467
Announcement Date 7/27/17 7/26/18 7/25/19 7/28/20 7/23/21 4/28/23
1HKD in Million2HKD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 399 498 448 288 92.4 224
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 31.4 58.3 -118 -123 -184 102
ROE (net income / shareholders' equity) 2.98% 2.61% 1.88% 1.12% -3.34% -2.74%
ROA (Net income/ Total Assets) 1.17% 0.96% 0.57% 0.61% -2.08% -2.4%
Assets 1 1,061 1,042 470.2 512.4 1,306 2,277
Book Value Per Share 2 0.3600 0.3900 0.3600 0.3400 0.3500 0.2900
Cash Flow per Share 2 0.1900 0.2300 0.1800 0.1400 0.1100 0.1600
Capex 1 2.8 8.63 33.6 93.9 146 33.3
Capex / Sales 1.43% 2.39% 6.38% 19.11% 30.71% 6.09%
Announcement Date 7/27/17 7/26/18 7/25/19 7/28/20 7/23/21 4/28/23
1HKD in Million2HKD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
TIANDA PHARMACEUTICALS LIMITED Stock Tianda Pharmaceuticals Limited
+21.56% 72.78M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 455 Stock
  4. Financials Tianda Pharmaceuticals Limited